Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases

NCT02532244 — Completed, 230 participants, Nemours Children's Clinic

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT02532244
StatusCompleted
Study typeObservational
Enrollment230 (Actual)
SponsorNemours Children's Clinic (Other)
ConditionsSpinal Muscular Atrophy, Charcot-Marie-Tooth Disease, Muscular Dystrophy, Spinal Muscular Atrophy With Respiratory Distress 1, Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Disease, Peroneal Muscular Atrophy
Interventionssample collection (Other)
Datesstart 2015-06-01, primary completion 2024-12-18, completion 2024-12-18, first posted 2015-08-25, last updated 2024-12-19
Locations3 sites in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Spinal Muscular Atrophy All trials for Charcot-Marie-Tooth Disease All trials of sample collection

-Summary

The goal of this study is to establish a genetic registry of patients with early-onset motor neuron and neuromuscular diseases. The investigators will collect samples from patients with a motor neuron or a neuromuscular disorder and their family members. The samples to be collected will be obtained using minimally invasive (whole blood) means. The research team will then extract high quality genomic DNA or RNA from these samples and use it to identify and confirm novel gene mutations and to identify genes which regulate the severity of motor neuron/neuromuscular diseases.

Expand all sections  ·  Collapse all

+Detailed description

Diseases affecting the motor unit--which is composed of the motor neuron, its myelin sheath and its innervated muscle fibers--are a diverse, heterogeneous group having heterogeneous clinical presentations and genetic causes. Many of these disorders have a inherited component. In some cases, the genetics underlying a given neuromuscular/motor neuron disease, like spinal muscular atrophy (SMA) or Duchenne muscular dystrophy, are well characterized. There are, however, disorders whose genetic basis has yet to be determined or genetically characterized diseases which harbor novel mutations. The purpose of this genetic registry is to catalogue early-onset motor neuron and neuromuscular disorders and to determine their genetic bases. With samples obtained from this registry, the investigators will be able to provide a genetic diagnosis for a specific neuromuscular/motor neuron disease which will lead to better care for those patients affected by these diseases.

Many of these disorders have a wide spectrum of phenotypic variability. For example, the severity of SMA is quite variable even though it is caused by the loss of a single gene, i.e. survival motor neuron 1 (SMN1). The number of copies of the duplicated gene survival motor neuron 2 (SMN2) dictates phenotypic severity in SMA. In this study, the research team will also identify potential modifiers of phenotypic severity for specific disorders like SMA and Charcot-Marie-Tooth (CMT) disease. With the identification of novel modifier genes, the investigators will be able to more accurately predict disease outcomes and the investigators will also have novel targets for the development of therapeutic agents for these diseases.

+Arms and interventions

ArmTypeInterventionsDescription
sample collectionOther: sample collectionEach participant will have blood drawn for genetic analysis and for establishment of a lymphoblastoid cell line.
  • sample collection (Other): collection of blood

+Outcome measures

Primary outcomes

  • genetic diagnosis [up to 2 years]: The genetic basis for the subject's condition will be verified/determined by Sanger sequencing of DNA sample

Secondary outcomes

  • SMN1 copy number [up to 2 years]: The number of copies of the SMN1 gene will be determined using array digital polymerase chain reaction (PCR).
  • SMN2 copy number [up to 2 years]: The number of copies of the SMN2 gene will be determined using array digital PCR.
  • target gene mRNA levels [up to 2 years]: The relative levels of the disease gene-specific messenger ribonucleic acid (mRNA) will be measured using quantitative PCR.
  • target gene protein levels [up to 2 years]: The relative amounts of the disease-gene-specific protein will be measured using immunoblot.

+Eligibility

Sex: All, ages: 1 Month to any, accepts healthy volunteers

Inclusion Criteria:

* Diagnosis of motor neuron/neuromuscular disease confirmed by neurologist
* Be seen by one of the study investigators

Exclusion Criteria:

* not seen by one of the study investigators

+Locations (3)

FacilityCityCountryStatus
Nemours Children's Hospital DelawareWilmington, DelawareUnited States
Nemours Children's Specialty CareJacksonville, FloridaUnited States
Nemours Children's Hospital OrlandoOrlando, FloridaUnited States

+Publications

  • Results publication: Stabley DL, Holbrook J, Harris AW, Swoboda KJ, Crawford TO, Sol-Church K, Butchbach MER. Establishing a reference dataset for the authentication of spinal muscular atrophy cell lines using STR profiling and digital PCR. Neuromuscul Disord. 2017 May;27(5):439-446. doi: 10.1016/j.nmd.2017.02.002. Epub 2017 Feb 6. PMID 28284873
  • Results publication: Stabley DL, Harris AW, Holbrook J, Chubbs NJ, Lozo KW, Crawford TO, Swoboda KJ, Funanage VL, Wang W, Mackenzie W, Scavina M, Sol-Church K, Butchbach ME. SMN1 and SMN2 copy numbers in cell lines derived from patients with spinal muscular atrophy as measured by array digital PCR. Mol Genet Genomic Med. 2015 Jul;3(4):248-57. doi: 10.1002/mgg3.141. Epub 2015 Mar 21. PMID 26247043
  • Results publication: Chen X, Sanchis-Juan A, French CE, Connell AJ, Delon I, Kingsbury Z, Chawla A, Halpern AL, Taft RJ; NIHR BioResource; Bentley DR, Butchbach MER, Raymond FL, Eberle MA. Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data. Genet Med. 2020 May;22(5):945-953. doi: 10.1038/s41436-020-0754-0. Epub 2020 Feb 18. PMID 32066871
  • Results publication: Jiang L, Lin R, Gallagher S, Zayac A, Butchbach MER, Hung P. Development and validation of a 4-color multiplexing spinal muscular atrophy (SMA) genotyping assay on a novel integrated digital PCR instrument. Sci Rep. 2020 Nov 16;10(1):19892. doi: 10.1038/s41598-020-76893-7. PMID 33199817
  • Results publication: Stabley DL, Holbrook J, Scavina M, Crawford TO, Swoboda KJ, Robbins KM, Butchbach MER. Detection of SMN1 to SMN2 gene conversion events and partial SMN1 gene deletions using array digital PCR. Neurogenetics. 2021 Mar;22(1):53-64. doi: 10.1007/s10048-020-00630-5. Epub 2021 Jan 7. PMID 33415588
  • Results publication: Pinto A, Cunha C, Chaves R, Butchbach MER, Adega F. Comprehensive In Silico Analysis of Retrotransposon Insertions within the Survival Motor Neuron Genes Involved in Spinal Muscular Atrophy. Biology (Basel). 2022 May 27;11(6):824. doi: 10.3390/biology11060824. PMID 35741345

+Investigators